# US Clinical Genomics Market > US Clinical Genomics Market Research Report By Test Type (Diagnostic Testing, Genetic Testing, Newborn Screening, Preimplantation Testing, Prenatal Testing, Carrier Testing, Other Tests), By Method (Molecular Tests, Chromosomal Tests, Biochemical Tests) and By End User (Hospitals & Clinics, Government Laboratories & Research Centres, Academics and Research Institutes, Other End Users) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 17.56% - **2024:** $ 302 Million - **2025:** $ 355.03 Million - **2035:** $ 1,790 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), Qiagen (DE), BGI Genomics (CN), Myriad Genetics (US), PerkinElmer (US), Genomatix (DE) **Report ID:** MRFR/HS/18356-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-clinical-genomics-market-19903 --- ## Market Summary ## **US Clinical Genomics Market Overview** As per MRFR analysis, the US Clinical Genomics Market Size was estimated at 216.51 (USD Million) in 2023. The US Clinical Genomics Market Industry is expected to grow from 250 (USD Million) in 2024 to 1,500 (USD Million) by 2035. The US Clinical Genomics Market CAGR (growth rate) is expected to be around 17.69% during the forecast period (2025 - 2035). ### **Key US Clinical Genomics Market Trends Highlighted** In the US Clinical Genomics Market, important trends are emerging that shape the landscape of healthcare. Growing awareness among healthcare providers and patients about the benefits of genomic testing has led to a surge in demand for personalized medicine, which tailors treatment based on an individual's genetic makeup. This trend is supported by advancements in sequencing technology, making genomic testing more accessible and affordable. Furthermore, regulations and initiatives by the US government, such as the Precision Medicine Initiative, are driving research and innovation in genomics. Notable opportunities lie in expanding the application of genomic testing in various domains, including oncology, rare diseases, and infectious diseases. As healthcare systems emphasize preventive measures, there is potential for genomic testing to play a critical role in early diagnosis and risk assessment. The integration of artificial intelligence within genomic analysis is another opportunity being explored, as it can enhance the interpretation of genomic data and improve patient outcomes. Trends in recent times showcase an increased collaboration between academic institutions, biotechnology firms, and healthcare providers. This collaboration aims to foster innovation and streamline the development of new genomic tests and treatments. Additionally, the shift towards telemedicine has facilitated easier access to genomic consultations, making it easier for patients to engage in their genomic health. Ultimately, these ongoing trends signify a major evolution within the US Clinical Genomics Market, reflecting a commitment to enhancing patient care through state-of-the-art genomic solutions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Clinical Genomics Market Drivers** ### **Increasing Prevalence of Genetic Disorders** The frequency of genetic disorders in the United States has seen a notable rise, with the Centers for Disease Control and Prevention (CDC) reporting that approximately 1 in 33 babies are born with a congenital disability. This statistic highlights a consistent demand for clinical genomics tools that aid in diagnosis and treatment planning. As the US [Clinical Genomics Market](../../../reports/clinical-genomics-market-12080) Industry continues to evolve, established organizations such as the National Institutes of Health (NIH) are driving innovation in genetic research and technology, fostering advancements in gene therapy and personalized medicine. The estimated increase in genetic testing and advanced therapeutic options further exemplifies the market potential, fueling growth. Moreover, the integration of genomic testing into standard medical care is being supported by healthcare providers, expecting to facilitate early interventions and treatment pathways, thus contributing to the overall growth trajectory of the market. ### **Technological Advancements in Genomic Sequencing** Technological innovations in genomic sequencing have significantly lowered the cost and time required for genetic analysis, contributing to the growth of the US Clinical Genomics Market Industry. According to the Human Genome Project, the cost of sequencing a human genome has dropped from approximately $1 billion in 2001 to around $600 as of recent years due to advancements in next-generation sequencing (NGS) technologies. This dramatic decrease in cost makes genomic testing more accessible to healthcare providers and patients alike. Companies such as Illumina, which leads the market with advanced sequencing technologies, are playing a crucial role in this trend. These advancements not only enhance research capabilities but also pave the way for personalized medicine, where treatments can be tailored based on individual genomics, thus attracting further investments in the clinical genomics sector. ### **Growing Demand for Personalized Medicine** The shift toward personalized medicine is reshaping healthcare in the United States, boosting the US Clinical Genomics Market Industry significantly. A recent report from the Food and Drug Administration (FDA) indicated that over 50% of new drugs approved in recent years have a companion diagnostic that relies on genomic information to determine the most effective treatment. This emphasis on individualized care aligns with a patient-centered approach that is rapidly gaining traction in the healthcare system. The rising number of clinical trials focusing on personalized therapies and the involvement of pharmaceutical companies in genetic testing further underpin this demand. Organizations such as the Genomic Medicine Institute are leading efforts to integrate genomics into clinical settings, driving growth and innovation in the US Clinical Genomics Market. ### **Supportive Government Policies and Funding** Government support plays a pivotal role in the evolution of the US Clinical Genomics Market Industry, ensuring funding for research and development initiatives. Legislative measures like the 21st Century Cures Act have not only accelerated the integration of genomic approaches in clinical practices but have also provided necessary financial backing for genomics research. The National Institutes of Health (NIH) reported a steep boost in budget allocations for genomics research, totaling over $2.4 billion annually. This commitment fosters an environment conducive to innovation and collaboration among healthcare providers, academic institutions, and biotechnology companies. As public funding continues to support the advancement of clinical genomics technologies and treatments, the overall market is expected to witness substantial growth and contributions towards improved patient outcomes. ## **US Clinical Genomics Market Segment Insights** ### **Clinical Genomics Market Test Type Insights** The Test Type segment of the US Clinical Genomics Market showcases an important facet of healthcare that is rapidly gaining traction due to advancements in technology and increasing consumer awareness regarding genetic conditions. This segment encompasses various categories, including Diagnostic Testing, Genetic Testing, Newborn Screening, Preimplantation Testing, Prenatal Testing, Carrier Testing, and Other Tests, all of which play a crucial role in early detection and personalized medicine. As the awareness around genetic disorders increases, the demand for these tests is on the rise, driven by both healthcare providers and patients. Trends such as the integration of genomics with IT systems, incorporation of artificial intelligence in data analysis, and the rise of telemedicine are enhancing the accessibility and efficiency of testing services. The growing prevalence of genetic disorders in the US necessitates an expansion of testing capabilities, creating opportunities for innovation and growth within this segment. Regulatory bodies are also focusing on providing robust frameworks to ensure the safety and effectiveness of these tests, further supporting market development. The Test Type segment is not just about testing; it signifies a paradigm shift towards personalized and preventive healthcare, catering to the needs of a diverse US population while fostering advancements in medical research and practice. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Clinical Genomics Market Method Insights** The US Clinical Genomics Market is significantly influenced by various methods employed in genomic testing, which include Molecular Tests, Chromosomal Tests, and Biochemical Tests. Molecular Tests play a crucial role in identifying genetic mutations responsible for various diseases, making them vital for personalized medicine and targeted therapies. As these methods continue to evolve, they drive the growth of the US Clinical Genomics Market, particularly through advancements in technology and increasing demand for precision medicine. The increasing emphasis on early disease detection and tailored treatment options presents a favorable environment for these methods to thrive, while also posing challenges related to regulatory standards and technological integration within healthcare systems. Overall, the emphasis on these methods highlights their critical importance in enhancing genomic care and improving patient outcomes in the United States. ### **Clinical Genomics Market End User Insights** The US Clinical Genomics Market, particularly focused on the End User segment, comprises a diverse range of entities, each playing a crucial role in the expansion and development of genomics applications. Hospitals and Clinics are integral as they facilitate the implementation of genomic testing in patient care, supporting personalized medicine initiatives. This segment's growth is strongly influenced by rising investments in genomic research, an increasing prevalence of genetic disorders, and the mounting demand for personalized healthcare solutions, making it a crucial component of the US Clinical Genomics Market ecosystem. The collaboration among these entities paves the way for pioneering services, which in turn drives innovation and addresses critical healthcare needs in the region. ## **US Clinical Genomics Market Key Players and Competitive Insights** The US Clinical Genomics Market is characterized by a dynamic environment marked by rapid technological advancements, increased investment in research and development, and a growing recognition of the importance of genomics in personalized medicine. The competitive landscape is shaped by a mix of established companies and emerging players, each striving to carve out a niche in the market. Key trends driving competition include the rise of next-generation sequencing technologies, the push toward integrated healthcare solutions, and increasing collaborations between biotech firms, pharmaceutical companies, and academic institutions. With the demand for genomic testing and personalized care on the rise, understanding competitive dynamics is essential for stakeholders to navigate this strategic market. ### **Illumina** Illumina is a dominant player within the US Clinical Genomics Market, known largely for its cutting-edge sequencing technology that has revolutionized genomic research and clinical applications. The company has built a robust portfolio of products, including sequencing platforms, reagents, and bioinformatics tools that have become industry standards. Strengths of Illumina include its continuous investment in innovation and its commitment to expanding the applications of its technology in healthcare settings, including oncology and genetic disorders. With a strong market presence, Illumina maintains a leadership position through strategic partnerships and collaborations that enhance its product offerings and expand its reach into various genomic analysis markets. ### **Precision Medicine Group** Precision Medicine Group is also a notable entity in the US Clinical Genomics Market, providing a unique blend of services that support companies and health systems in improving patient outcomes through genomic insights. The firm focuses on contemporary services like clinical trial design, regulatory consulting, and commercialization strategies, aligning with the needs of precision medicine stakeholders. Key products and services from Precision Medicine Group include disease-specific registries and patient engagement platforms, enabling improved patient stratification and treatment pathways. The company has strengthened its position through strategic mergers and acquisitions, which have enhanced its service capabilities and expanded its market presence. This approach facilitates their ability to leverage cutting-edge genomics data for actionable clinical insights, thereby reinforcing their role in shaping the future of personalized healthcare within the United States. ### **Key Companies in the US Clinical Genomics Market Include** ## **US Clinical Genomics Market Industry Developments** Recent developments in the US Clinical Genomics Market have focused on advancements in genetic testing and precision medicine, particularly as companies like Illumina and Thermo Fisher Scientific continue to innovate. In October 2023, Illumina announced a partnership with Qiagen to enhance cancer diagnostics, combining their genomic technologies for improved patient outcomes. Furthermore, Myriad Genetics has expanded its testing portfolio, focusing on hereditary cancer in response to increasing demand from healthcare providers. Current affairs include the rise in valuations among these companies, with Roche acquiring Spark Therapeutics in 2019, enhancing its gene therapy capabilities. Additionally, Agilent Technologies reported growth in sales driven by its genomic services. The US government has also amplified its support for personalized medicine initiatives, promoting research and funding through agencies such as the National Institutes of Health (NIH). In 2021, Guardant Health went public, further spotlighting the market's potential, with investors showing increasing interest in companies focusing on non-invasive genomic testing. The overall market dynamics indicate a robust push towards integration of genomic data in clinical practices, a trend that will likely continue to gain momentum in the coming years. ## **US Clinical Genomics Market Segmentation Insights** ### **Clinical Genomics Market Test Type Outlook** ### **Clinical Genomics Market Method Outlook** ### **Clinical Genomics Market End User Outlook** ## Market Drivers ### Expansion of Reimbursement Policies The clinical genomics market is positively influenced by the expansion of reimbursement policies for genetic testing and genomic services. As insurers increasingly recognize the value of genomic testing in improving patient care and reducing long-term costs, more comprehensive coverage options are being introduced. This shift is particularly evident in the US, where several major insurance providers have begun to cover a wider range of genetic tests. The increased availability of reimbursement not only alleviates the financial burden on patients but also encourages healthcare providers to incorporate genomic testing into their practice. This trend is likely to stimulate growth in the clinical genomics market as more patients gain access to essential genomic services. ### Rising Demand for Precision Medicine The clinical genomics market is experiencing a notable surge in demand for precision medicine, which tailors treatment based on individual genetic profiles. This shift is driven by an increasing recognition of the limitations of traditional one-size-fits-all approaches. In the US, the precision medicine market is projected to reach approximately $100 billion by 2026, indicating a robust growth trajectory. As healthcare providers and patients alike seek more effective treatment options, the integration of genomic data into clinical practice is becoming essential. This trend not only enhances patient outcomes but also drives the clinical genomics market forward, as more healthcare systems invest in genomic technologies to support personalized treatment plans. ### Growing Public Awareness and Education Public awareness and education regarding the benefits of genomic testing are playing a crucial role in the growth of the clinical genomics market. As individuals become more informed about the potential of genomics to influence health outcomes, there is a corresponding increase in demand for genetic testing services. Educational initiatives by healthcare organizations and advocacy groups are helping to demystify genomic technologies and their applications. This heightened awareness is likely to lead to greater acceptance of genomic testing among patients and healthcare providers alike. Consequently, the clinical genomics market is expected to expand as more individuals seek out genomic insights to inform their healthcare decisions. ### Increased Focus on Preventive Healthcare The clinical genomics market is benefiting from a growing emphasis on preventive healthcare strategies. As healthcare systems in the US shift towards proactive measures, genomic testing is increasingly viewed as a vital tool for identifying individuals at risk for various diseases. This proactive approach not only aims to improve patient outcomes but also seeks to reduce healthcare costs associated with late-stage disease management. The market for preventive genomics is expected to grow significantly, with estimates indicating a compound annual growth rate (CAGR) of over 15% in the coming years. This trend underscores the importance of integrating genomic insights into preventive healthcare initiatives, thereby driving the clinical genomics market. ### Technological Advancements in Genomic Sequencing Technological advancements in genomic sequencing are significantly impacting the clinical genomics market. Innovations such as next-generation sequencing (NGS) have drastically reduced the cost and time required for genomic analysis. The price of sequencing a human genome has plummeted from around $100 million in 2001 to less than $1,000 today. This dramatic decrease has made genomic testing more accessible to healthcare providers and patients, thereby expanding the market. Furthermore, the development of user-friendly platforms for genomic data interpretation is facilitating the integration of genomic information into routine clinical practice, which is likely to enhance the overall efficiency and effectiveness of healthcare delivery. ## Future Outlook The [Clinical Genomics Market](https://www.marketresearchfuture.com/reports/clinical-genomics-market-12080) is projected to grow at a 17.56% CAGR from 2025 to 2035, driven by advancements in technology, increasing demand for personalized medicine, and rising healthcare expenditure. **New opportunities:** - Development of AI-driven genomic analysis platforms Expansion of direct-to-consumer genetic testing services Integration of genomics in precision oncology treatment plans By 2035, the clinical genomics market is expected to be robust, reflecting substantial growth and innovation. ## Segment Insights ### By Test Type: Diagnostic Testing (Largest) vs. Genetic Testing (Fastest-Growing) In the US clinical genomics market, Diagnostic Testing holds the largest market share among the various test types available, reflecting its critical role in disease identification and management. This segment has established itself as a primary choice for healthcare providers and patients, driven by the increasing demand for accurate and timely diagnostic solutions. In contrast, Genetic Testing, while smaller in share, is rapidly gaining traction due to rising consumer awareness and advancements in technology that enhance testing capabilities. The growth trend in Genetic Testing is fueled by factors such as a greater emphasis on personalized medicine, evolving healthcare policies, and expanding applications in various medical fields. As more healthcare professionals recognize the benefits of genetic insights, the demand for these tests is expected to escalate. Additionally, market players are innovating new testing methods and offering comprehensive panels, contributing to the growth of this emerging segment, which is projected to experience significant expansion in the coming years. Diagnostic Testing (Dominant) vs. Genetic Testing (Emerging) Diagnostic Testing is characterized by its established dominance within the US clinical genomics market, recognized for its reliability and precision in identifying diseases. It encompasses a wide array of techniques, including molecular diagnostics, which have undergone significant advancements. Patients and clinicians favor Diagnostic Testing for its accuracy, leading to swift treatment decisions. Conversely, Genetic Testing is an emerging segment showing robust growth potential, driven by a surge in genetic disorders awareness and the benefits of early detection. Innovations in sequencing technologies are enabling more comprehensive testing options, increasing its appeal. As healthcare shifts toward more individualized treatment strategies, both segments are becoming pivotal in addressing the evolving needs of patients. ### By Method: Molecular Tests (Largest) vs. Chromosomal Tests (Fastest-Growing) The market share distribution among the method segment values in the US clinical genomics market reveals that Molecular Tests hold the largest portion, driven by widespread adoption and integration into various healthcare practices. Chromosomal Tests and Biochemical Tests follow, each contributing distinct roles in diagnostics and treatment, but with Molecular Tests leading the charge in innovations and applications. Growth trends indicate that the US clinical genomics market is rapidly expanding, particularly with Chromosomal Tests emerging as the fastest-growing segment. Factors such as increasing incidence of genetic disorders, technological advancements in testing methodologies, and the push for personalized medicine are catalyzing this growth. Furthermore, regulatory support and rising healthcare expenditures contribute significantly to market dynamics. Molecular Tests (Dominant) vs. Biochemical Tests (Emerging) Molecular Tests are a dominant force in the US clinical genomics market, characterized by their high accuracy and ability to detect genetic material at a granular level. This segment benefits from advanced technologies such as PCR and next-generation sequencing, catering to a broad array of applications from oncology to infectious diseases. In contrast, Biochemical Tests represent an emerging segment that offers unique insights into metabolic and enzymatic functions within the body. While they currently capture a smaller market share, developments in technology and methodologies are positioning Biochemical Tests to progressively gain traction, especially in personalized health approaches and preventative screening. ### By End User: Hospitals & Clinics (Largest) vs. Academics and Research Institutes (Fastest-Growing) In the US clinical genomics market, the end user segment is predominantly driven by Hospitals & Clinics, which capture a significant share due to the increasing integration of genomic data into clinical settings. This allows for personalized medicine and improved patient outcomes. Government Laboratories & Research Centres also hold a valuable share, facilitating research and developing new genomic technologies. In contrast, Academics and Research Institutes are growing steadily as they push the boundaries of genetic research and collaboration with healthcare providers. The growth in the end user segment is fueled by advancements in genomic sequencing technologies and the rising need for personalized healthcare solutions. Hospitals & Clinics are investing heavily in genomic diagnostics to enhance treatment plans, while Academics and Research Institutes are becoming pivotal in innovation, driving research related to disease genomics. This shift is supported by increased funding from government and private sectors to promote genetic studies, emphasizing collaborative efforts to leverage genomic insights. Hospitals & Clinics (Dominant) vs. Academics and Research Institutes (Emerging) Hospitals & Clinics are the dominant players in the US clinical genomics market, leveraging genomic data for improved patient diagnostics and treatment. Their investment in advanced sequencing technologies and clinical collaborations drives significant growth, enabling personalized medicine and enhancing healthcare delivery. Meanwhile, Academics and Research Institutes represent an emerging segment by focusing on fundamental research and innovation in genomics. They are instrumental in training the next generation of genomic scientists and developing breakthroughs in genetic therapies. Their collaborative nature often leads to partnerships with industry players, fostering a dynamic environment that accelerates the application of genomics in clinical settings. Together, these segments play crucial roles in advancing the field of genomics. ## Competitive Benchmarking The clinical genomics market is characterized by a dynamic competitive landscape. This landscape is driven by rapid advancements in technology and an increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Myriad Genetics (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Illumina (US) focuses on innovation in sequencing technologies, while Thermo Fisher Scientific (US) emphasizes a broad portfolio of genomic solutions, including reagents and instruments. Myriad Genetics (US) is leveraging its expertise in hereditary cancer testing to expand its offerings in precision medicine. Collectively, these strategies contribute to a competitive environment that is increasingly centered on technological advancement and customer-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive innovation through their extensive research and development efforts. In October Illumina (US) announced a strategic partnership with a leading healthcare provider to integrate its genomic sequencing technology into routine clinical practice. This collaboration is expected to enhance patient access to genomic testing, thereby solidifying Illumina's position as a leader in the market. The strategic importance of this partnership lies in its potential to accelerate the adoption of genomic medicine, aligning with the growing trend towards personalized healthcare. In September Thermo Fisher Scientific (US) launched a new line of next-generation sequencing (NGS) products aimed at improving the efficiency of genomic research. This product launch is significant as it not only expands Thermo Fisher's product portfolio but also reinforces its commitment to innovation in genomic technologies. The introduction of these advanced tools is likely to attract a broader customer base, enhancing the company's competitive edge. In August Myriad Genetics (US) expanded its genetic testing services by acquiring a smaller firm specializing in rare disease diagnostics. This acquisition is strategically important as it diversifies Myriad's offerings and positions the company to tap into the growing market for rare disease testing. By broadening its service range, Myriad is likely to enhance its market presence and appeal to a wider audience. As of November current trends in the clinical genomics market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into genomic research and diagnostics. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of developing robust, cutting-edge solutions that meet the evolving needs of healthcare providers and patients alike. ## Recent News & Developments Recent developments in the US Clinical Genomics Market have focused on advancements in genetic testing and precision medicine, particularly as companies like Illumina and Thermo Fisher Scientific continue to innovate. In October 2023, Illumina announced a partnership with Qiagen to enhance cancer diagnostics, combining their genomic technologies for improved patient outcomes. Furthermore, Myriad Genetics has expanded its testing portfolio, focusing on hereditary cancer in response to increasing demand from healthcare providers. Current affairs include the rise in valuations among these companies, with Roche acquiring Spark Therapeutics in 2019, enhancing its gene therapy capabilities. Additionally, Agilent Technologies reported growth in sales driven by its genomic services. The US government has also amplified its support for personalized medicine initiatives, promoting research and funding through agencies such as the National Institutes of Health (NIH). In 2021, Guardant Health went public, further spotlighting the market's potential, with investors showing increasing interest in companies focusing on non-invasive genomic testing. The overall market dynamics indicate a robust push towards integration of genomic data in clinical practices, a trend that will likely continue to gain momentum in the coming years. ## Report Scope | MARKET SIZE 2024 | 302.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 355.03(USD Million) | | MARKET SIZE 2035 | 1790.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.56% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), Qiagen (DE), BGI Genomics (CN), Myriad Genetics (US), PerkinElmer (US), Genomatix (DE) | | Segments Covered | Test Type, Method, End User | | Key Market Opportunities | Advancements in personalized medicine drive demand for innovative solutions in the clinical genomics market. | | Key Market Dynamics | Technological advancements drive innovation and competition in the clinical genomics market, reshaping healthcare delivery and patient outcomes. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the projected market valuation for the US clinical genomics market by 2035?** A: The projected market valuation for the US clinical genomics market by 2035 is $1790.0 Million. **Q: What was the market valuation for the US clinical genomics market in 2024?** A: The market valuation for the US clinical genomics market in 2024 was $302.0 Million. **Q: What is the expected CAGR for the US clinical genomics market during the forecast period 2025 - 2035?** A: The expected CAGR for the US clinical genomics market during the forecast period 2025 - 2035 is 17.56%. **Q: Which companies are considered key players in the US clinical genomics market?** A: Key players in the US clinical genomics market include Illumina, Thermo Fisher Scientific, Roche, Agilent Technologies, Qiagen, BGI Genomics, Myriad Genetics, PerkinElmer, and Genomatix. **Q: What are the main segments of the US clinical genomics market?** A: The main segments of the US clinical genomics market include Test Type, Method, and End User. **Q: What is the valuation range for diagnostic testing in the US clinical genomics market?** A: The valuation range for diagnostic testing in the US clinical genomics market is $60.0 Million to $350.0 Million. **Q: How much is the genetic testing segment valued in the US clinical genomics market?** A: The genetic testing segment is valued between $80.0 Million and $450.0 Million in the US clinical genomics market. **Q: What is the projected valuation for molecular tests in the US clinical genomics market?** A: The projected valuation for molecular tests in the US clinical genomics market ranges from $120.0 Million to $700.0 Million. **Q: Which end user segment has the highest valuation in the US clinical genomics market?** A: The Hospitals & Clinics segment has the highest valuation in the US clinical genomics market, ranging from $120.0 Million to $680.0 Million. **Q: What is the valuation range for prenatal testing in the US clinical genomics market?** A: The valuation range for prenatal testing in the US clinical genomics market is $50.0 Million to $300.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-clinical-genomics-market-19903*